Abeona Therapeutics Inc P/E
What is the P/E of Abeona Therapeutics Inc?
The P/E of Abeona Therapeutics Inc is 0.00
What is the definition of P/E?
Price to earnings ratio is the ratio of a company’s stock price to the company’s earnings per share calculated over trailing twelve months.
= previous day’s close / ttm EPS
The price to earnings ratio is the most widely used method for determining whether shares are accurately valued in relation to one another. But the P/E ratio does not in itself indicate whether the share is a bargain. The P/E ratio depends on the market’s perception of the risk and future growth in earnings. A company with a low P/E ratio indicates that the market perceives it as a higher risk or a lower growth or both as compared to a company with a higher price to earnings ratio. The P/E ratio of a listed company’s stock is the result of the collective perception of the market as to how risky the company is and what its earnings growth prospects are in relation to that of other companies. Investors use the P/E ratio to compare their own perception of the risk and growth of a company against the market’s collective perception of the risk and growth as reflected in the current P/E ratio.
P/E of companies in the Health Care sector on NASDAQ compared to Abeona Therapeutics Inc
What does Abeona Therapeutics Inc do?
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
Companies with p/e similar to Abeona Therapeutics Inc
- Richland Resources International has P/E of N/A
- Safeplus International has P/E of N/A
- China Yanyuan Yuhui Natl Ed Grp has P/E of N/A
- Acusphere has P/E of N/A
- American Oriental Bioengineering has P/E of N/A
- Gourmet Provisions International has P/E of N/A
- Abeona Therapeutics Inc has P/E of 0.00
- SEL Manufacturing has P/E of 0.00
- China Zhong Qi Hldgs has P/E of 0.00
- MedSmart has P/E of 0.00
- Panbela Therapeutics has P/E of 0.00
- Epic has P/E of 0.00
- 2574 has P/E of 0.00